As of 2025-03-22, the EV/EBITDA ratio of Cytokinetics Inc (CYTK) is -10.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CYTK's latest enterprise value is 5,941.63 mil USD. CYTK's TTM EBITDA according to its financial statements is -546.32 mil USD. Dividing these 2 quantities gives us the above CYTK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 14.8x | 13.4x |
| Forward P/E multiples | 21.8x - 47.9x | 34.8x |
| Fair Price | (105.33) - (73.03) | (116.06) |
| Upside | -331.8% - -260.8% | -355.5% |
| Date | EV/EBITDA |
| 2025-03-18 | -10.41 |
| 2025-03-17 | -10.76 |
| 2025-03-14 | -10.64 |
| 2025-03-13 | -10.65 |
| 2025-03-12 | -10.56 |
| 2025-03-11 | -10.65 |
| 2025-03-10 | -10.42 |
| 2025-03-07 | -10.44 |
| 2025-03-06 | -10.41 |
| 2025-03-05 | -10.54 |
| 2025-03-04 | -10.50 |
| 2025-03-03 | -10.33 |
| 2025-02-28 | -11.00 |
| 2025-02-27 | -11.31 |
| 2025-02-26 | -11.19 |
| 2025-02-25 | -11.14 |
| 2025-02-24 | -11.46 |
| 2025-02-21 | -11.92 |
| 2025-02-20 | -12.11 |
| 2025-02-19 | -11.09 |
| 2025-02-18 | -10.87 |
| 2025-02-14 | -11.03 |
| 2025-02-13 | -10.05 |
| 2025-02-12 | -10.17 |
| 2025-02-11 | -10.04 |
| 2025-02-10 | -10.18 |
| 2025-02-07 | -10.30 |
| 2025-02-06 | -11.04 |
| 2025-02-05 | -11.96 |
| 2025-02-04 | -11.69 |
| 2025-02-03 | -11.53 |
| 2025-01-31 | -11.75 |
| 2025-01-30 | -11.86 |
| 2025-01-29 | -11.57 |
| 2025-01-28 | -11.58 |
| 2025-01-27 | -11.85 |
| 2025-01-24 | -12.03 |
| 2025-01-23 | -11.40 |
| 2025-01-22 | -11.18 |
| 2025-01-21 | -10.96 |
| 2025-01-17 | -10.94 |
| 2025-01-16 | -11.21 |
| 2025-01-15 | -11.19 |
| 2025-01-14 | -10.83 |
| 2025-01-13 | -11.15 |
| 2025-01-10 | -11.13 |
| 2025-01-08 | -11.30 |
| 2025-01-07 | -11.54 |
| 2025-01-06 | -11.69 |
| 2025-01-03 | -11.73 |